Researchers have found a link between low testosterone levels and aggressive tumors, which could change how prostate cancer ...

What is circulating tumor DNA (ctDNA) in prostate cancer? Learn how this blood test helps track disease and guide treatment.

Low testosterone levels may increase the risk of higher-grade “extreme” progression of prostate cancer among men enrolled in active surveillance (AS), acc ...

Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity ...

USA: A retrospective cohort study has found that low testosterone levels in patients with prostate cancer undergoing active ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive ...

Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate ...

Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the ...

Results challenge view that high testosterone fuels prostate cancer growth ...

Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

The statistics are sobering and undeniable — African American men develop prostate cancer at twice the rate of white men and are more likely to die from the disease. This reality makes understanding ...

Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic ...